The following extracts from EP3439644 - ISOFLAVONOID COMPOSITION WITH IMPROVED PHARMACOKINETICS speak for themselves:
- 30 April 2021: Annex to the [Examiner] communication
- Adaption of the Description
- It appears that the claims may meet the requirement of the EPC
- The Applicant is therefore requested to bring the description into conformity with the claims.
- 14 May 2021 [Noxopharm patent attorney]
- I note with thanks the Examining Division's acknowledgement that the claims meet the requirement of the EPC
- I enclose replacement pages of the description …
I also draw attention to US20190262451 – RADIOTHERAPY IMPROVEMENTs
- 11 May 2021
- As seen above, claim 3 has, the only independent claim, has been significantly amended. These amendments are in response to suggestions made by the examiner during the telephonic interview. It is applicant’s view that the examiner agrees that abscopal effects are by their very nature unpredictable …
Patent facts
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |